Free Trial

BioMarin Pharmaceutical (BMRN) Earnings Date, Estimates & Call Transcripts

BioMarin Pharmaceutical logo
$62.06 +0.03 (+0.05%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$60.85 -1.21 (-1.95%)
As of 07:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioMarin Pharmaceutical Earnings Summary

Latest Q4
Earnings Date
Feb. 19Estimated
Consensus EPS
(Feb. 19)
$0.54
Actual EPS
(Feb. 19)
$0.72 Beat By $0.18
Actual Revenue
(Feb. 19)
$747.31M

BioMarin Pharmaceutical posted Q4 2024 earnings on February 19, 2025, reporting an EPS of $0.72, which beat the consensus estimate of $0.54 by $0.18. Quarterly revenue was reported to be $747.31 million, above analyst estimates of $711.05 million. With a trailing EPS of $2.69 and a P/E Ratio of 28.21, BioMarin Pharmaceutical's earnings are expected to grow 38.41% next year, from $3.15 to $4.36 per share.

Q4 2024 Earnings Resources

Get BioMarin Pharmaceutical Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioMarin Pharmaceutical and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

BMRN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BMRN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BioMarin Pharmaceutical Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany EPS GuidanceCompany Revenue Guidance
Q1 20253$0.48$0.77$0.65
Q2 20253$0.73$0.94$0.82
Q3 20253$0.82$0.90$0.85
Q4 20253$0.67$0.91$0.80
FY 2025 12 $2.70 $3.52 $3.12
Q1 20262$0.91$0.93$0.92
Q2 20262$0.97$0.99$0.98
Q3 20262$0.98$1.05$1.02
Q4 20261$1.13$1.13$1.13

BioMarin Pharmaceutical Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
2/19/2025Q4 2024$0.54$0.72+$0.18$0.64$711.05M$747.31M
10/29/2024Q3 2024$0.78$0.55 -$0.23$0.93$703.37M$746.00M
8/5/2024Q2 2024$0.38$0.77+$0.39$0.99$660.51M$712.03M
4/24/2024Q1 2024$0.37$0.49+$0.12$0.52$649.75M$648.83M
2/22/2024Q4 2023$0.4450$0.49+$0.0450$0.41$639.53M$646.21M
11/1/2023Q3 2023$0.28$0.26 -$0.02$0.31$603.51M$581.33M
7/31/2023Q2 2023$0.24$0.34+$0.10$0.39$591.46M$595.28M

BioMarin Pharmaceutical Earnings - Frequently Asked Questions

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earning data on Wednesday, February 19, 2025. Learn more on BMRN's earnings history.

BioMarin Pharmaceutical issued an update on its FY 2025 earnings guidance on Thursday, May, 1st. The company provided earnings per share (EPS) guidance of 4.200-4.400 for the period, compared to the consensus estimate of 4.300. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

In the previous quarter, BioMarin Pharmaceutical (NASDAQ:BMRN) reported $0.72 earnings per share (EPS) to beat the analysts' consensus estimate of $0.54 by $0.18. Learn more on analysts' earnings estimate vs. BMRN's actual earnings.

The conference call for BioMarin Pharmaceutical's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for BioMarin Pharmaceutical's latest earnings report can be read online.
Read Transcript

BioMarin Pharmaceutical's earnings report can be found in their filing with the SEC.
View SEC filing

BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded annual revenue of $2.95 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded net income of $167.65 million. BMRN has generated $2.69 earnings per share over the last four quarters.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a trailing price-to-earnings ratio of 28.21 and a forward price-to-earnings ratio of 19.70. The price/earnings-to-growth ratio is 0.61.

BioMarin Pharmaceutical's earnings are expected to grow from $3.15 per share to $4.36 per share in the next year, which is a 38.41% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:BMRN) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners